PatientsVille.com Logo

HEART RATE INCREASED and Ramipril

PatientsVille

HEART RATE INCREASED Symptoms and Causes

An arrhythmia is a problem with the rate or rhythm of your heartbeat. It means that your heart beats too quickly, too slowly, or with an irregular pattern. When the heart beats faster than normal, it is called tachycardia. When the heart beats too slowly, it is called bradycardia. The most common type of arrhythmia is atrial fibrillation, which causes an irregular and fast heart beat.

Many factors can affect your heart's rhythm, such as having had a heart attack, smoking, congenital heart defects, and stress. Some substances or medicines may also cause arrhythmias.

Symptoms of arrhythmias include

  • Fast or slow heart beat
  • Skipping beats
  • Lightheadedness or dizziness
  • Chest pain
  • Shortness of breath
  • Sweating

Your doctor can run tests to find out if you have an arrhythmia. Treatment to restore a normal heart rhythm may include medicines, an implantable cardioverter-defibrillator (ICD) or pacemaker, or sometimes surgery.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for HEART RATE INCREASED

HEART RATE INCREASED treatment research studies

Ramipril clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ramipril Side Effects

Renal Failure Acute (252)
Dyspnoea (156)
Angioedema (149)
Hypotension (148)
Dizziness (130)
Cough (125)
Dehydration (107)
Nausea (105)
Hyperkalaemia (104)
Hyponatraemia (97)
Diarrhoea (95)
Confusional State (91)
Syncope (87)
Vomiting (87)
Malaise (85)
Fall (82)
Fatigue (78)
Chest Pain (78)
Headache (77)
Asthenia (75)
Swollen Tongue (65)
Lip Swelling (64)
Blood Pressure Increased (63)
Blood Creatinine Increased (62)
Cardiac Failure (62)
Hypoaesthesia (61)
Pruritus (58)
Palpitations (55)
Renal Failure (55)
Loss Of Consciousness (54)
Hypertension (52)
Haemoglobin Decreased (48)
Atrial Fibrillation (47)
Condition Aggravated (47)
Somnolence (45)
Pain In Extremity (44)
Paraesthesia (43)
Rash (42)
Abdominal Pain (41)
Hyperhidrosis (39)
Overdose (38)
Pneumonia (38)
International Normalised Ratio Increased (38)
Depression (37)
Vision Blurred (36)
Renal Impairment (36)
Lactic Acidosis (36)
Bradycardia (36)
Sepsis (35)
Myalgia (35)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Aside from auto-bruising and some annoying balance problems the ultimate killer was an attack of light-headedness !! Incidentally my Doctor at the time refused to even discuss side effects let alone assist in mitigating !! Needless to say I fir

Can Ramipril ranbaxy cause itchiness and if so, is it best to avoid this medication?

Can I take ciprofloxacin with my medicines for diabetes

Extreme uncontrolled coughing for 6 weeks

Hi i have been on ramipril about 4 years now. but i am also taking amlopdine'simvastatin'tramadol'naproxen'and lansoprazole.which are causing all sorts problems such as extreme muscle pain and stomach pain swollen eyelids swollen throat rashes. inso

I am 48 and have been on rampiril 5mg along with crestor 5mg since the last 8 months. I have been experiencing irritation in my throat, very dry throat and severe cough. at times I suspect this is due to rampiril. I am otherwise fit and have had no

I am taking rampihil 5 mg a day. I have a cough. Blurred vision. Dizzy. And i have now had 3 outbreaks of genital herpes since taking it in mid may 2011. What is your opinion?

I can sympathise with the back pain i have it in between my shoulders and there are times I could cry it hurts so but my GP says its not the meds but it only started when I started taking these tablets I too have found lots of comments on the interne

I get the same dry throat this is a common side effect.

I had very similar symptoms and would even double up with the pain. Would only easy when I vomitted. However, now I do get the gas attacks and bloated feeling, but the body seesm to have got used to it

Yesterday, after taking Sam-e with Glucosamine. I got a pain between my shoulder blade, jaw pain, dizziness, sweating. felt like a heart attack. I did not go to the hospital because of the money needed. No ins

I took chapmix over 2 years ago and have been smoke free ever since, which I am very pleased about. However, I have had some issues with my heart, starting about a year ago with irregular, very rapid heartbeats. Finally I went through a whole

After using Clobetasol for a two week cycle, my doctor suggested I use it one day during the week, applying it twice that day. Since that time, I have experinced severe chest pain. I recently saw my doctor for heart attack symptoms before I reali

i had heart failure last august 2010, among other tablets i have been taking emconcor. i wonder whether these tablets are responsible for making my limbs feel weak, and lightheaded.

I HAD 1 SHOT OF THIS AND WITHIN 12 HOURS I WENT FROM A VERY NORMAL BLOOD PRESSURE TO WAKING AT 5 A.M. NEXT DAY WITH 198/110 AND 104 PULSE RATE. IT HAS CONTINUED ALL WEEK AFTER AND I'M NOW ON A BLOOD PRESSURE DRUG TO TRY AND CONTROL IT. EVEN WITH DR

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

I am real tired I've been on coreg about two weeks, I don't know if Ican keep taking it. I am so sleepy all the time don't want to do anything my chest hurts. Don't know what to do, if Idon't take it my heart want work right. JUST STUCK

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

fell dizziness and was admitted. Doc execute with dianostic including blood teat and heart check all. good. Doc make a decision by saying i'm getting Vertigo and treat with BETASERC. Below is the effect after 2 days take this medicine:- I was

HEART RATE INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy
Conditions: Diabetes Type 2;   Diabetic Nephropathy;   Vascular Disease
Interventions: Drug: Ramipril;   Drug: Clopidogrel
Outcome Measures: Changes in Asymmetric dimethylarginine (ADMA) blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in High-sensitivity C-reactive protein (HsCRP) blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in soluble CD40 Ligand (sCD40L)blood levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in urine 8-isoprostane-F2 levels after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Reduction in albumine to creatine ratio after the combined treatment with Ramipril and clopidogrel compared with Ramipril monotherapy;   Changes in ADMA blood levels after treatment with Ramipril;   Increase of Glomerular Filtration Rate (GFR) after combined treatment with Ramipril and clopidogrel and after Ramipril monotherapy;   Change from baseline in carotid intima-media thickness after combined therapy with Ramipril and clopidogrel and after Ramipril monotherapy
2 Recruiting Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Condition: Metabolic Syndrome
Interventions: Drug: Ramipril;   Drug: HCTZ-hydrochlorothiazide;   Drug: Ramipril+HCTZ
Outcome Measure: Changes in Insulin Sensitivity
3 Recruiting Ramipril for the Treatment of Oligospermia
Conditions: Oligospermia;   Teratospermia;   Asthenozoospermia;   Male Infertility
Interventions: Drug: Ramipril;   Drug: Placebo
Outcome Measures: Sperm density in infertile men with documented oligospermia.;   Total Motile Sperm Count(TMSC), total sperm count, sperm motility, and morphology in the ejaculate.;   Pregnancy rate;   Hormonal profile
4 Unknown  Clinical and Cost Effectiveness of ACE Inhibitor, Ramipril, in Intermittent Claudicants
Condition: Intermittent Claudicants
Intervention: Drug: Ramipril
Outcome Measures: The primary outcome measure for this trial is the Maximum Walking Distance (MWD). Treadmill exercise test will be used to estimate the maximum distance the participant can walk at a speed of 2.5 km/h with a 10 degree incline.;   Other clinical indicators of lower limb ischaemia: a) Patient Reported Walking Distance (PRWD) b) Treadmill Intermittent Claudication Distance (ICD) c) Ankle Brachial Pressure Index at rest (ABPI- r) and following treadmill testing (ABPI - t);   Quality of life: a) Generic - measured using the SF36, SF8 and EuroQol (EQ5D) instruments b) Disease specific - measured using the VascuQol;   Cardiovascular prognosis using: a) Framingham, PROCAM, QRISK and Manchester charts scoring systems b) B-type Natriuretic Peptide (BNP) and N- terminal prohormone BNP (NT-proBNP) and a Lipid profile ( LDL, HDL, Total Cholesterol, Triglycerides);   Markers of endothelial function and ischaemia reperfusion a) IL6 b) soluble Intercellular Adhesion Molecule-1 (sICAM -1) c) sE selectin d) Urine Albumin Creatinine Ratio ( UACR);   Arterial effects: a) Arterial stiffness by measuring the Pulse Wave Velocity and assessing the effects on the extracellular matrix by measuring Metalloproteinases (MMPs) and Tissue Inhibitor Metalloproteinases (TIMPs). b) Flow mediated vasodilatation;   Health economics (cost effectiveness / utility)
5 Unknown  Left Atrial Remodelling in Hypertension: Effects of Ramipril or Irbesartan
Conditions: Left Atrial Volume;   Hypertensive Heart Disease;   Antihypertensive Drugs;   Diastolic Function;   Renin Angiotensin System
Interventions: Drug: Ramipril;   Drug: irbesartan
Outcome Measures: left atrial volume;   diastolic function;   systolic and diastolic blood pressure
6 Unknown  Antiproteinuric Effect of Imidapril Versus Ramipril in Type 2 Diabetic and Hypertensive Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes Mellitus;   Microalbuminuria
Interventions: Drug: Ramipril;   Drug: Imidapril
Outcome Measures: Size of the reduction of urinary albumin in 24 hours to the various controls;   1. Size of the reduction of mean 24-hour average daytime and nighttime average. 2. Size of the reduction of central blood pressure. 3. Magnitude of changes in plasma concentrations of angiotensin II, bradykinin and BNP after 24 weeks of treatment.
7 Not yet recruiting Aliskiren Study of Safety and Efficacy in Senior Hypertensives
Condition: Hypertension
Interventions: Drug: Aliskiren;   Drug: Amlodipine;   Drug: Ramipril;   Drug: Hydrochlorothiazide
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (MSSBP) to week 8;   Number of patients with serious adverse events and adverse events;   Number of patients with hyperkalemia, hypotension and reduction of estimated glomerular filtration rate (eGFR);   Change from baseline in mean sitting systolic blood pressure (MSSBP) at the end of double blind period;   Percentage of patients achieving blood pressure control;   Percentage of patients with major cardiovascular events;   Number of patients with gastrointestinal tract cancer
8 Unknown  Ramipril Versus Carvedilol in Duchenne and Becker Patients
Conditions: Duchenne Muscular Dystrophy;   Becker Muscular Dystrophy
Interventions: Drug: carvedilol;   Drug: Ramipril
Outcome Measures: Left ventricular Ejection Fraction, systolic and diastolic left ventricular volumes and LGE (as a quantitative measure) detected by MRI and myocardial Ultrasound Tissue Characterisation data by Echocardiography.;   Prevalence of LGE in DMD and BMD patients,the effects of pharmacological therapy both on LGE evolution and myocardial UTC analysis.
9 Unknown  Aliskiren Versus Ramipril on Antiproteinuric Effect in Hypertensive, Type 2 Diabetic Patients With Microalbuminuria
Conditions: Hypertension;   Type 2 Diabetes
Interventions: Drug: Ramipril;   Drug: Experimental
Outcome Measures: Antiproteinuric effect as well as antihypertensive effect of aliskiren 300 mg / daily versus Ramipril 10 mg daily in hypertensive patients with type 2 diabetes and microalbuminuria.;   Average of 24 hours by ABPM, systolic and diastolic blood pressure;   Average daytime, systolic and diastolic blood pressure;   Average night, systolic and diastolic blood pressure
10 Recruiting Efficacy and Safety Study to Delay Renal Failure in Children With Alport Syndrome
Condition: Renal Insufficiency, Chronic
Interventions: Drug: Ramipril;   Drug: placebo to Ramipril
Outcome Measures: Time to next disease level;   Incidence of Adverse Drug Events before progression;   Albuminuria after three years;   Adverse Drug Events over three years
11 Unknown  Telmisartan Versus Ramipril After Acute Coronary Syndrome
Conditions: Acute Coronary Syndrome;   Myocardial Infarction;   Coronary Disease
Interventions: Drug: TELMISARTAN;   Drug: Ramipril
Outcome Measures: High sensitivity C-Reactive Protein;   Endothelial Progenitor Cells
12 Recruiting Impact of Body Composition on Bisoprolol and Ramipril Pharmacokinetics in Patients With Chronic Heart Failure
Conditions: Chronic Heart Failure;   Cachexia
Intervention:
Outcome Measures: Pharmacokinetic parameters of bisoprolol and Ramipril;   Body composition;   Cachexia diagnosis;   Renal function
13 Not yet recruiting Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD
Condition: Coronary Artery Dissection, Spontaneous
Interventions: Drug: Ramipril;   Drug: rosuvastatin;   Drug: placebo
Outcome Measures: Angina frequency domain of the SAQ;   Acute coronary syndrome or hospitalization for angina
14 Recruiting Sevelamer in Proteinuric CKD
Condition: Chronic Kidney Disease
Interventions: Drug: Sevelamer;   Drug: Ramipril and Irbesartan
Outcome Measures: 24-h urinary protein excretion;   Office blood pressure;   Glomerular Filtration Rate
15 Recruiting Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3
Conditions: Oxidative Stress;   Endothelial Dysfunction
Interventions: Drug: Ramipril (ACE inhibitor);   Drug: valsartan (ARB);   Drug: Placebo
Outcome Measures: To compare the long term effects of ACE inhibition or angiotensin receptor blockade versus placebo on biomarkers of fibrinolysis, oxidative stress and inflammation in patients with chronic kidney disease undergoing maintenance hemodialysis;   To compare the long term effects of ACE inhibition or AT1 receptor blockade versus placebo on carotid intima-media thickness (IMT) in patients with chronic kidney disease undergoing maintenance hemodialysis;   Track safety endpoints- hyperkalemia, hypotension, nonfatal myocardial infarction, nonfatal stroke, death from cardiac causes, fatal stroke, death due to any cause.
16 Unknown  Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity
Condition: Metabolic Syndrome X
Interventions: Drug: Eplerenone;   Drug: Ramipril
Outcome Measures: Secreted factors from adipocytes have autocrine, paracrine and endocrine effects that have a deleterious effect on the fibrinolytic system, either by enhancing PAI-1 production or impairing endothelial t-PA release;   This study will analyze patients' genetic make up to identify who may be at greater risk for heart disease and strokes in relationship to high blood pressure and central obesity.
17 Not yet recruiting Cardiac Energetics and Function in Normal Human Ageing
Conditions: Left Ventricular Function Systolic Dysfunction;   Left Ventricular Function Diastolic Dysfunction;   Ageing
Intervention: Drug: Ramipril
Outcome Measures: Vascular Stiffness;   Left Ventricular Energetics;   Left Ventricular Function;   Effects of ACE inhibitor on left ventricular energetics and function in those subjects aged 40 and over
18 Not yet recruiting Effect of Chronic ACE and DPP4 Inhibition on Blood Pressure
Conditions: Type 2 Diabetes Mellitus;   Hypertension
Interventions: Drug: Placebo;   Drug: Sitagliptin;   Drug: Aprepitant
Outcome Measures: Blood pressure;   heart rate;   norepinephrine (NE) concentrations;   Low frequency variability of blood pressureactivity, aldosterone;   glucose;   insulin;   DPP4 activity;   ACE
19 Recruiting Prevention of Atrial Fibrillation by Inhibition Conversion Enzyme (ICE) After Radiofrequency Ablation of Atrial Flutter
Conditions: Atrial Fibrillation;   Atrial Flutter
Interventions: Drug: Ramipril;   Drug: Placebo
Outcome Measures: At least one relevant symptomatic or asymptomatic atrial fibrillation event;   All relevant cardiovascular event;   Secondary effects of the treatment
20 Recruiting Fixed Dose Combination Drug (Polypill)for Secondary Cardiovascular Prevention.
Condition: Myocardial Infarction
Interventions: Drug: FDC;   Drug: Separately drugs, simvastatin, aspirin and Ramipril
Outcome Measures: Proportion of patients receiving AAS, an ACE inhibitor and a statin among those without contraindications to any of these drugs Adherence to treatment measured by: Morinsky-Green test and Pill accountability.;   Adherence to treatment measured by the Morisky-Green questionnaire;   Treatment adherence measured by: Morisky-Green test: (Good adherence score 16-20) at 1 and 9 months.;   Treatment adherence measured by: Pill counts at 1-4-9 months. (Good adherence 80-110% PC);   Blood Pressure and Lipid Profile (LDL-cholesterol) at 1 and 9 months;   Safety and tolerability: Adverse events and rate of treatment withdrawal.